Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman.
Abdominal migraine
Abdominal pain
Child
Oman
Pizotifen
Riboflavin
Journal
Pediatric gastroenterology, hepatology & nutrition
ISSN: 2234-8646
Titre abrégé: Pediatr Gastroenterol Hepatol Nutr
Pays: Korea (South)
ID NLM: 101590471
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
04
07
2021
revised:
19
11
2021
accepted:
06
02
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
2
4
2022
Statut:
ppublish
Résumé
Abdominal migraine (AM) is a very common functional gastrointestinal disorder in children. This study reports the clinical features and response of AM to prophylactic treatment in children. This retrospective study was conducted between January 2010 and December 2019 at the Royal Hospital in the Sultanate of Oman. This study included children aged ≤ 13 years with a diagnosis of AM based on the Rome IV criteria for functional diagnoses. Clinical, demographic, and treatment data were collected. Seventy-four children were identified, of which 43 were eligible for inclusion in this study. The median age at the onset of symptoms was 7 years (range, 2-12 years). The most frequent symptoms were headache (81.4%), nausea (79.1%), and vomiting (72.1%). Of the total cohort, 46.5%, 23.3%, and 6.9% received riboflavin, pizotifen, and propranolol monotherapy, respectively. Combination therapy was also used; 16.3% of children received pizotifen and propranolol, 4.7% received riboflavin and pizotifen, and 2.3% received riboflavin and propranolol. Patients treated with propranolol monotherapy showed 100% clinical improvement and those treated with riboflavin or pizotifen monotherapy showed 90% clinical improvement. Response to combination therapy with pizotifen and propranolol was 71.4%, and with riboflavin and pizotifen was 100%. In addition, treatment response was significantly associated with the presence of vomiting ( We found a favorable response to various modalities and combination treatments with riboflavin, pizotifen, and propranolol in children with AM. In addition, the presence of vomiting may predict treatment response.
Identifiants
pubmed: 35360376
doi: 10.5223/pghn.2022.25.2.121
pmc: PMC8958052
doi:
Types de publication
Journal Article
Langues
eng
Pagination
121-128Informations de copyright
Copyright © 2022 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors have no financial conflicts of interest.
Références
J Pediatr. 2018 Aug;199:212-216
pubmed: 29747935
Headache. 2011 May;51(5):707-12
pubmed: 21395574
Neurology. 1994 Apr;44(4):666-9
pubmed: 8164822
Headache. 1990 Oct;30(10):642-5
pubmed: 2272813
J Headache Pain. 2009 Oct;10(5):361-5
pubmed: 19649688
Pediatr Neurol. 2010 Jan;42(1):1-11
pubmed: 20004856
BMJ. 2018 Feb 19;360:k179
pubmed: 29459383
J Pediatr. 2014 Mar;164(3):542-5.e1
pubmed: 24332822
Gastroenterology. 2016 Feb 15;:
pubmed: 27144632
Nat Rev Gastroenterol Hepatol. 2015 Mar;12(3):159-71
pubmed: 25666642
J Pediatr Gastroenterol Nutr. 2005 Mar;40(3):249-61
pubmed: 15735476
Neurology. 1998 Feb;50(2):466-70
pubmed: 9484373
Neurology. 1992 Jun;42(6):1209-14
pubmed: 1603349
Arch Dis Child. 1995 Jan;72(1):48-50
pubmed: 7717738
Arch Dis Child. 1995 May;72(5):413-7
pubmed: 7618907
Cephalalgia. 2013 Jul;33(9):629-808
pubmed: 23771276
Cephalalgia. 2004;24 Suppl 1:9-160
pubmed: 14979299
J Pediatr Gastroenterol Nutr. 1999 Jan;28(1):37-40
pubmed: 9890466
Pediatric Health Med Ther. 2018 Apr 24;9:47-58
pubmed: 29733088